Cargando…
Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
AIMS: Repeated risk assessments and treatment patterns over long time are sparsely studied in chronic thromboembolic pulmonary hypertension (CTEPH); thus, we aimed to investigate changes in risk status and treatment patterns in incident patients with CTEPH over a 5 year period. METHODS AND RESULTS:...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715829/ https://www.ncbi.nlm.nih.gov/pubmed/35789127 http://dx.doi.org/10.1002/ehf2.14033 |
_version_ | 1784842544667951104 |
---|---|
author | Kjellström, Barbro Bouzina, Habib Björklund, Erik Beaudet, Amélie Edwards, Susan C. Hesselstrand, Roger Jansson, Kjell Nisell, Magnus Rådegran, Göran Sandqvist, Anna Wåhlander, Håkan Hjalmarsson, Clara Söderberg, Stefan |
author_facet | Kjellström, Barbro Bouzina, Habib Björklund, Erik Beaudet, Amélie Edwards, Susan C. Hesselstrand, Roger Jansson, Kjell Nisell, Magnus Rådegran, Göran Sandqvist, Anna Wåhlander, Håkan Hjalmarsson, Clara Söderberg, Stefan |
author_sort | Kjellström, Barbro |
collection | PubMed |
description | AIMS: Repeated risk assessments and treatment patterns over long time are sparsely studied in chronic thromboembolic pulmonary hypertension (CTEPH); thus, we aimed to investigate changes in risk status and treatment patterns in incident patients with CTEPH over a 5 year period. METHODS AND RESULTS: Descriptive and explorative study including 311 patients diagnosed with CTEPH 2008–2019 from the Swedish pulmonary hypertension registry, stratified by pulmonary endarterectomy surgery (PEA). Risk and PH‐specific treatment were assessed in surgically treated (PEA) and medically treated (non‐PEA) patients at diagnosis and up to 5 years follow‐up. Data are presented as median (Q1–Q3), count or per cent. Prior to surgery, 63% in the PEA‐group [n = 98, age 64 (51–71) years, 37% female] used PH‐specific treatment and 20, 69, and 10% were assessed as low, intermediate or high risk, respectively. After 1 year post‐surgery, 34% had no PH‐specific treatment or follow‐up visit registered despite being alive at 5 years. Of patients with a 5 year visit (n = 23), 46% were at low and 54% at intermediate risk, while 91% used PH‐specific treatment. In the non‐PEA group [n = 213, age 72 (65–77) years, 56% female], 28% were assessed as low, 61% as intermediate and 11% as high risk. All patients at high risk versus 50% at low risk used PH‐specific treatment. The 1 year mortality was 6%, while the risk was unchanged in 57% of the patients; 14% improved from intermediate to low risk, and 1% from high to low risk. At 5 years, 27% had a registered visit and 28% had died. Of patients with a 5 year visit (n = 58), 38% were at low, 59% at intermediate and 1% at high risk, and 86% used PH‐specific treatment. CONCLUSIONS: Risk status assessed pre‐surgery did not foresee long‐term post‐PEA risk and pre‐surgery PH‐specific treatment did not foresee long‐term post‐PEA treatment. Medically treated CTEPH patients tend to remain at the same risk over time, suggesting a need for improved treatment strategies in this group. |
format | Online Article Text |
id | pubmed-9715829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97158292022-12-05 Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension Kjellström, Barbro Bouzina, Habib Björklund, Erik Beaudet, Amélie Edwards, Susan C. Hesselstrand, Roger Jansson, Kjell Nisell, Magnus Rådegran, Göran Sandqvist, Anna Wåhlander, Håkan Hjalmarsson, Clara Söderberg, Stefan ESC Heart Fail Original Articles AIMS: Repeated risk assessments and treatment patterns over long time are sparsely studied in chronic thromboembolic pulmonary hypertension (CTEPH); thus, we aimed to investigate changes in risk status and treatment patterns in incident patients with CTEPH over a 5 year period. METHODS AND RESULTS: Descriptive and explorative study including 311 patients diagnosed with CTEPH 2008–2019 from the Swedish pulmonary hypertension registry, stratified by pulmonary endarterectomy surgery (PEA). Risk and PH‐specific treatment were assessed in surgically treated (PEA) and medically treated (non‐PEA) patients at diagnosis and up to 5 years follow‐up. Data are presented as median (Q1–Q3), count or per cent. Prior to surgery, 63% in the PEA‐group [n = 98, age 64 (51–71) years, 37% female] used PH‐specific treatment and 20, 69, and 10% were assessed as low, intermediate or high risk, respectively. After 1 year post‐surgery, 34% had no PH‐specific treatment or follow‐up visit registered despite being alive at 5 years. Of patients with a 5 year visit (n = 23), 46% were at low and 54% at intermediate risk, while 91% used PH‐specific treatment. In the non‐PEA group [n = 213, age 72 (65–77) years, 56% female], 28% were assessed as low, 61% as intermediate and 11% as high risk. All patients at high risk versus 50% at low risk used PH‐specific treatment. The 1 year mortality was 6%, while the risk was unchanged in 57% of the patients; 14% improved from intermediate to low risk, and 1% from high to low risk. At 5 years, 27% had a registered visit and 28% had died. Of patients with a 5 year visit (n = 58), 38% were at low, 59% at intermediate and 1% at high risk, and 86% used PH‐specific treatment. CONCLUSIONS: Risk status assessed pre‐surgery did not foresee long‐term post‐PEA risk and pre‐surgery PH‐specific treatment did not foresee long‐term post‐PEA treatment. Medically treated CTEPH patients tend to remain at the same risk over time, suggesting a need for improved treatment strategies in this group. John Wiley and Sons Inc. 2022-07-04 /pmc/articles/PMC9715829/ /pubmed/35789127 http://dx.doi.org/10.1002/ehf2.14033 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Kjellström, Barbro Bouzina, Habib Björklund, Erik Beaudet, Amélie Edwards, Susan C. Hesselstrand, Roger Jansson, Kjell Nisell, Magnus Rådegran, Göran Sandqvist, Anna Wåhlander, Håkan Hjalmarsson, Clara Söderberg, Stefan Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension |
title | Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension |
title_full | Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension |
title_fullStr | Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension |
title_full_unstemmed | Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension |
title_short | Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension |
title_sort | five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715829/ https://www.ncbi.nlm.nih.gov/pubmed/35789127 http://dx.doi.org/10.1002/ehf2.14033 |
work_keys_str_mv | AT kjellstrombarbro fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT bouzinahabib fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT bjorklunderik fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT beaudetamelie fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT edwardssusanc fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT hesselstrandroger fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT janssonkjell fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT nisellmagnus fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT radegrangoran fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT sandqvistanna fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT wahlanderhakan fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT hjalmarssonclara fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension AT soderbergstefan fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension |